Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1-845-458-6882

TGF-β SIGNALING IS A NOVEL THERAPEUTIC TARGET FOR TREATING METASTATIC CANCERS ACQUIRED BY EMT AND CANCER STEMNESS

11th International Conference on Cancer Stem Cells and Oncology Research
June 11-13, 2018 | Dublin, Ireland

Seong-Jin Kim

Seoul National University, Korea

Scientific Tracks Abstracts : J Med Oncl Ther

Abstract:

TGF-β is a multifunctional cytokine involved in diverse cellular functions, including cell growth and immune responses. TGF-β signaling has emerged as a key architect of the microenvironment in poor-prognosis cancers. Disseminated tumor cells show a strong dependency on a TGFβ-activated stromal during the establishment and subsequent expansion of metastasis. TGF-β also has a positive role on the cancer stem cell (CSC) population promoting or sustaining stemness of the pool of CSCs in diverse types of malignancy. Since TGF-β signaling is dysregulation most of human cancers, thus affecting the overall progression to malignancy, TGF-β signaling has been considered a potentially novel therapeutic target for treating resistance acquired by emptying the TGF-β signaling pathway, TGF-β receptor I kinase inhibitors have shown promise in blocking the TGF-β-mediated tumor progression and metastasis and enhancing antitumor immunity in nonclinical animal models. Vactosertib, a TGF-β receptor I kinase inhibitor, has shown significant preclinical antitumor efficacy in a range of in vivo metastatic and orthotopic xenograft models and has completed phase 1 clinical trials in USA. Recent molecular classification of gastrointestinal cancer has identified a poor-prognosis transcriptional subtype associated with mesenchymal traits and genes upregulated by TGF-β in stromal cells are robust predictors of cancer recurrence and metastasis. This observation warrants the development of anti-TGF-β therapies for the treatment of poor-prognosis cancers with TGF-β response signature.

Biography:

Seong-Jin Kim is currently working as a professor at the PrecisionMedicine Research Center at the Advanced Institute of Convergence Technology, Seoul National University, Korea.

Email:[email protected]

PDF HTML
Get the App

Bursa implant